Frontiers journals are at the top of citation and impact metrics

This article is part of the Research Topic

Vascular Calcification

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Cardiovasc. Med. | doi: 10.3389/fcvm.2018.00183

The Interplay of SIRT1 and Wnt signalling in Vascular Calcification

  • 1Manchester Metropolitan University, United Kingdom

Vascular calcification is a major health risk and is highly correlated with atherosclerosis, diabetes and chronic kidney disease. The development of vascular calcification is an active and complex process linked with a multitude of signalling pathways, which regulate promoters and inhibitors of osteogenesis, the balance of which become deregulated in disease conditions. SIRT1, a protein deacetylase, known to be protective in inhibiting oxidative stress and inflammation within the vessel wall, has been shown as a possible key player in modulating the cell-fate determining canonical Wnt signalling pathways. Suppression of SIRT1 has been reported in patients suffering with cardiovascular pathologies, suggesting that the sustained acetylation of osteogenic factors could contribute to their activation and in turn, lead to the progression of calcification. There is clear evidence of the synergy between β-Catenin and elevated Runx2, and with Wnt signalling being β-Catenin dependent, further understanding is needed as to how these molecular pathways converge and interact, in order to provide novel insight into the mechanism by which smooth muscle cells switch to an osteogenic differentiation programme. Therefore, this review will describe the current concepts of pathological soft tissue mineralisation, with a focus on the contribution of SIRT1 as a regulator of Wnt signalling and its targets, discussing SIRT1 as a potential target for manipulation and therapy

Keywords: SIRT 1, Wnt / b-catenin, diabetes, Calcifying cells, osteogenic markers, Vascular Calcification, RUNX2

Received: 07 Sep 2018; Accepted: 04 Dec 2018.

Edited by:

Dwight A. Towler, University of Texas Southwestern Medical Center, United States

Reviewed by:

Alexander N. Kapustin, AstraZeneca (United Kingdom), United Kingdom
Patricia B. Maguire, University College Dublin, Ireland  

Copyright: © 2018 Bartoli-Leonard, WILKINSON, Langford-Smith, Alexander and Weston. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Ria Weston, Manchester Metropolitan University, Manchester, United Kingdom, r.weston@mmu.ac.uk